Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 3, 2006. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares, executed under authority granted by shareholders at the Annual General Meeting on May 25, 2005.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 970,000 ordinary shares of 25 pence each.
- Purchase Date: May 3, 2006.
- Price Per Share: 1,543.4893 pence.
- Treasury Holdings Post-Transaction: 159,444,678 shares.
- Shares in Issue (excluding Treasury): 5,819,093,760 shares.
Material Changes
The material change reported is the reduction of outstanding shares through a buyback program. The company increased its treasury stock holdings by 970,000 shares. No other material changes to operations or financial position are disclosed in this specific filing.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities in any jurisdiction.
Key Facts for Investor Verification
- Verify the total cost of the repurchase by multiplying 970,000 shares by 1,543.4893 pence.
- Confirm the updated total share capital structure (5,819,093,760 shares in issue plus 159,444,678 treasury shares).
- Check subsequent filings to determine if this was an isolated transaction or part of a larger ongoing buyback program.
- Note that this filing does not contain quarterly or annual financial performance data.